250 related articles for article (PubMed ID: 16104036)
1. Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma.
Thieblemont C; Antal D; Lacotte-Thierry L; Delwail V; Espinouse D; Michallet AS; Traulle C; Bouafia-Sauvy F; Giraud C; Salles G; Guilhot F; Coiffier B
Cancer; 2005 Oct; 104(7):1434-41. PubMed ID: 16104036
[TBL] [Abstract][Full Text] [Related]
2. Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma.
Hess G; Flohr T; Huber C; Kolbe K; Derigs HG; Fischer T
Bone Marrow Transplant; 2003 May; 31(9):775-82. PubMed ID: 12732884
[TBL] [Abstract][Full Text] [Related]
3. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K
Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654
[TBL] [Abstract][Full Text] [Related]
4. [Use of Mabtera (rituximab) in treating patients with refractory courses of B-cell lymphoma, along with high-dose chemotherapy and autologous transplantation of hematopoietic stem cells].
Ptushkin VV; Chimishkian KL; Zhukov NV; Osmanov DSh; Andreeva LIu; Tupitsyn NN; Larionova VB; Mkheidze DM; Poddubnaia NV
Ter Arkh; 2003; 75(1):65-8. PubMed ID: 12652962
[TBL] [Abstract][Full Text] [Related]
5. Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large b-cell lymphoma: final results of a Phase II GOELAMS Study.
Dilhuydy MS; Lamy T; Foussard C; Gressin R; Casassus P; Deconninck E; Le Maignan C; Damotte D; Milpied N;
Biol Blood Marrow Transplant; 2010 May; 16(5):672-7. PubMed ID: 20045738
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
7. Rituximab: enhancing stem cell transplantation in mantle cell lymphoma.
Gianni AM; Cortelazzo S; Magni M; Martelli M;
Bone Marrow Transplant; 2002 Feb; 29 Suppl 1():S10-3. PubMed ID: 11840155
[TBL] [Abstract][Full Text] [Related]
8. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
[TBL] [Abstract][Full Text] [Related]
9. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
[TBL] [Abstract][Full Text] [Related]
10. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
Kanaji N; Ishibashi K; Uno H; Hino N
Gan To Kagaku Ryoho; 2002 Dec; 29(13):2569-72. PubMed ID: 12506485
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma.
Laudi N; Arora M; Burns L; McGlave P; Miller J; Bohac G; Rogers T; Barker J; Coad J; Weisdorf D
Am J Hematol; 2006 Jul; 81(7):519-24. PubMed ID: 16755570
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
Witzens-Harig M; Heilmann C; Hensel M; Kornacker M; Benner A; Haas R; Fruehauf S; Ho AD
Stem Cells; 2007 Jan; 25(1):228-35. PubMed ID: 17204607
[TBL] [Abstract][Full Text] [Related]
13. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.
Rummel MJ; Al-Batran SE; Kim SZ; Welslau M; Hecker R; Kofahl-Krause D; Josten KM; Dürk H; Rost A; Neise M; von Grünhagen U; Chow KU; Hansmann ML; Hoelzer D; Mitrou PS
J Clin Oncol; 2005 May; 23(15):3383-9. PubMed ID: 15908650
[TBL] [Abstract][Full Text] [Related]
14. Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma.
Murali S; Winton E; Waller EK; Heffner LT; Lonial S; Flowers C; Kaufman J; Arellano M; Lechowicz MJ; Mann KP; Khoury HJ; Langston AA
Bone Marrow Transplant; 2008 Oct; 42(8):529-34. PubMed ID: 18622414
[TBL] [Abstract][Full Text] [Related]
15. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.
Ritchie DS; Seymour JF; Grigg AP; Roberts AW; Hoyt R; Thompson S; Szer J; Prince HM
Ann Hematol; 2007 Feb; 86(2):101-5. PubMed ID: 17089127
[TBL] [Abstract][Full Text] [Related]
16. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
Romaguera JE; Fayad L; Rodriguez MA; Broglio KR; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Sarris AH; Dang NH; Wang M; Beasley V; Medeiros LJ; Katz RL; Gagneja H; Samuels BI; Smith TL; Cabanillas FF
J Clin Oncol; 2005 Oct; 23(28):7013-23. PubMed ID: 16145068
[TBL] [Abstract][Full Text] [Related]
17. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.
Sebban C; Brice P; Delarue R; Haioun C; Souleau B; Mounier N; Brousse N; Feugier P; Tilly H; Solal-Céligny P; Coiffier B
J Clin Oncol; 2008 Jul; 26(21):3614-20. PubMed ID: 18559872
[TBL] [Abstract][Full Text] [Related]
18. [Current strategies in the treatment of advanced stage mantle cell lymphoma].
Lenz G; Dreyling M; Unterhalt M; Hiddemann W
Dtsch Med Wochenschr; 2004 Nov; 129(45):2429-33. PubMed ID: 15529247
[TBL] [Abstract][Full Text] [Related]
19. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL.
Flohr T; Hess G; Kolbe K; Gamm H; Nolte H; Stanislawski T; Huber C; Derigs HG
Bone Marrow Transplant; 2002 May; 29(9):769-75. PubMed ID: 12040475
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
